- World Health Organization. Global hepatitis report 2024: action for access in low-and middle-income countries. April 9, 2024. Accessed January 15, 2025. https://www.who.int/publications/i/item/9789240091672
- World Health Organization. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022–2030. July 18, 2022. Accessed January 15, 2025. https://www.who.int/publications/i/item/9789240053779
- Centers for Disease Control and Prevention. 2022 viral hepatitis surveillance report. September 30, 2024. Accessed January 15, 2025. https://www.cdc.gov/hepatitis-surveillance-2022/about/index.html
Zhou K, Terrault NA. Gaps in viral hepatitis awareness in the United States in a population-based study. Clin Gastroenterol Hepatol. 2020;18(1):188-195.e4.
Tu T, Budzinska MA, Shackel NA, et al. HBV DNA integration: molecular mechanisms and clinical implications. Viruses. 2017;9(4):75.
Liang TJ. Hepatitis B: the virus and disease. Hepatology. 2009;49(5 suppl):S13-S21.
Chu CJ, Keeffe EB, Han SH, et al. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology. 2003;125(2):444-451.
Trépo C, Chan HLY, Lok A. Hepatitis B virus infection. Lancet. 2014;384(9959):2053-2063.
Papatheodoridis GV, Hadziyannis SJ. Diagnosis and management of pre-core mutant chronic hepatitis B. J Viral Hepat. 2001;8(5):311-321.
Suslov A, Meier MA, Ketterer S, et al. Transition to HBeAg-negative chronic hepatitis B virus infection is associated with reduced cccDNA transcriptional activity. J Hepatol. 2021;74(4):794-800.
Wilkins T, Sams R, Carpenter M. Hepatitis B: screening, prevention, diagnosis, and treatment. Am Fam Physician. 2019;99(5):314-323.
Fattovich G, Olivari N, Pasino M, et al. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut. 2008;57(1):84-90.
Zhou K, Contag C, Whitaker E, et al. Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses. Lancet Gastroenterol Hepatol. 2019;4(3):227-238.
Yeo YH, Ho HJ, Yang HI, et al. Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis. Gastroenterology. 2019;156(3):635-646.e9.
Calderon-Martinez E, Landazuri-Navas S, Vilchez E, et al. Prognostic scores and survival rates by etiology of hepatocellular carcinoma: a review. J Clin Med Res. 2023;15(4):200-207.
Conners EE, Panagiotakopoulos L, Hofmeister MG, et al. Screening and testing for hepatitis B virus infection: CDC recommendations - United States, 2023. MMWR Recomm Rep. 2023;72(1):1-25.
Toy M, Hutton D, Harris AM, et al. Cost-effectiveness of 1-time universal screening for chronic hepatitis B infection in adults in the United States. Clin Infect Dis. 2022;74(2):210-217.
Krist AH, Davidson KW, Mangione CM, et al. Screening for hepatitis B virus infection in adolescents and adults: US Preventive Services Task Force recommendation statement. JAMA. 2020;324(23):2415-2422.
Owens DK, Davidson KW, Krist AH, et al. Screening for hepatitis B virus infection in pregnant women: US Preventive Services Task Force reaffirmation recommendation statement. JAMA. 2019;322(4):349-354.
Tang LSY, Covert E, Wilson E, et al. Chronic hepatitis B infection: a review. JAMA. 2018;319(17):1802-1813.
Weng MK, Doshani M, Khan MA, et al. Universal hepatitis B vaccination in adults aged 19–59 years: updated recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(13):477-483.
Raimondo G, Locarnini S, Pollicino T, et al. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol. 2019;71(2):397-408.
Rehermann B. Toward a better understanding of chronic hepatitis B virus infection. J Clin Invest. 2024;134(19):e185568.
Spradling PR, Xing J, Harris AM, et al. Estimated prevalence and number of persons with isolated antibody to hepatitis B core antigen and associated occult hepatitis B, United States, 2001–2018. J Infect Dis. 2022;225(3):465-469.
Sandul AL, Rapposelli K, Nyendak M, et al. Updated recommendation for universal hepatitis B vaccination in adults aged 19–59 years - United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(48):1106.
Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018;67(1):1-31.
- American Academy of Family Physicians. Birth through age 18 immunization schedule. 2025. Accessed February 14, 2026. https://www.aafp.org/family-physician/patient-care/prevention-wellness/immunizations-vaccines/immunization-schedules/birth-through-age-18-immunization-schedule.html
Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-1599.
Stevens CE, Beasley RP, Tsui J, et al. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med. 1975;292(15):771-774.
Schillie S, Walker T, Veselsky S, et al. Outcomes of infants born to women infected with hepatitis B. Pediatrics. 2015;135(5):e1141-e1147.
Veronese P, Dodi I, Esposito S, et al. Prevention of vertical transmission of hepatitis B virus infection. World J Gastroenterol. 2021;27(26):4182-4193.
Surofchy DD, Shieh N, Tam I. Evolving considerations for choice of hepatitis B vaccine. Am J Manag Care. 2023;29(1 suppl):S3-S14.
Walsh C, McDaniel K, Lindsey L, et al. Seroconversion following Heplisav-B, hepatitis B vaccine (recombinant), adjuvanted, in patients with end-stage renal disease at an urban safety net hospital. Am J Health Syst Pharm. 2023;80(suppl 4):S130-S134.
Amjad W, Alukal J, Zhang T, et al. Two-dose hepatitis B vaccine (Heplisav-B) results in better seroconversion than three-dose vaccine (Engerix-B) in chronic liver disease. Dig Dis Sci. 2021;66(6):2101-2106.
Roberts H, Ly KN, Yin S, et al. Prevalence of HBV infection, vaccine-induced immunity, and susceptibility among at-risk populations: US households, 2013–2018. Hepatology. 2021;74(5):2353-2365.
Hall EW, Weng MK, Harris AM, et al. Assessing the cost-utility of universal hepatitis B vaccination among adults. J Infect Dis. 2022;226(6):1041-1051.
Marks KM, Kang M, Umbleja T, et al. HepB-CpG vs HepB-Alum vaccine in people with HIV and prior vaccine nonresponse. The Bee-HIVe randomized clinical trial. JAMA. 2025;333(4):295-306.
Dusheiko G. A shift in thinking to reduce mother-to-infant transmission of hepatitis B. N Engl J Med. 2018;378(10):952-953.
Samadi KG, Castillo E, Osman M, et al. Clinical course of 161 untreated and tenofovir-treated chronic hepatitis B pregnant patients in a low hepatitis B virus endemic region. J Viral Hepat. 2016;23(1):15-22.
Lin KW, Kirchner JT. Hepatitis B. Am Fam Physician. 2004;69(1):75-82.